Betahistine Hydrochloride 8 mg Uncoated Tablet

Betahistine Hydrochloride 8 mg Uncoated Tablet is a uncoated tablet formulated with 8 mg. The active ingredient profile is Betahistine Hydrochloride, placing the product in the antivertigo agent category. Betahistine is an antivertigo medicine used in selected vestibular disorders and should be described according to the approved local indication. The uncoated presentation is an oral solid-dosage form and should be described according to the approved finished-product specification. For website cataloguing, composition, strength, dosage form and release/coating characteristics should be displayed prominently and consistently. The description should remain factual and should not include unapproved cure, superiority, guaranteed-result or broad therapeutic claims. Clinical selection should depend on diagnosis, patient-specific factors, contraindications, concomitant medicines and the prescriber’s judgement. Prescription status, precautions, interactions, adverse effects and dosing must be checked against the current approved product label before publication. Manufacturer, licence, storage, shelf-life, pack configuration and market-specific regulatory details should be added only from verified product documentation.